{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:26:11Z","timestamp":1792045571125,"version":"4.4.0"},"reference-count":100,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,3,15]]},"abstract":"<jats:p>\n            There is an urgent global need for new strategies and drugs to control and treat multidrug-resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of 12 antibiotic-resistant priority pathogens and began to critically analyze the antibacterial clinical pipeline. This review analyzes \u201ctraditional\u201d and \u201cnontraditional\u201d antibacterial agents and modulators in clinical development current on 30 June 2021 with activity against the WHO priority pathogens mycobacteria and\n            <jats:named-content content-type=\"genus-species\">Clostridioides difficile<\/jats:named-content>\n            .\n          <\/jats:p>","DOI":"10.1128\/aac.01991-21","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T18:10:15Z","timestamp":1641838215000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":258,"title":["Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed"],"prefix":"10.1128","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6689-4236","authenticated-orcid":true,"given":"Mark S.","family":"Butler","sequence":"first","affiliation":[{"name":"MSBChem Consulting, Brisbane, Queensland, Australia"},{"name":"Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Gigante","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Division, WHO, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatim","family":"Sati","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Division, WHO, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Paulin","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Division, WHO, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Al-Sulaiman","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Division, WHO, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Rex","sequence":"additional","affiliation":[{"name":"F2G Limited, Eccles, Manchester, United Kingdom"},{"name":"McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhavathi","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Scientific Advisory Committee, GARDP, Geneva, Switzerland"},{"name":"The National Biodefense Science Board, U.S. Department of Health and Human Services, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar A.","family":"Arias","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research, Houston Methodist Research Institute, Houston, Texas, USA"},{"name":"Center for Infectious Diseases, UTHealth School of Public Health, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mical","family":"Paul","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, Rambam Health Care Campus, Haifa, Israel"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy E.","family":"Thwaites","sequence":"additional","affiliation":[{"name":"Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam"},{"name":"Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, Oxford University, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd","family":"Czaplewski","sequence":"additional","affiliation":[{"name":"Chemical Biology Ventures Ltd., Abingdon, Oxfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5056-7377","authenticated-orcid":true,"given":"Richard A.","family":"Alm","sequence":"additional","affiliation":[{"name":"CARB-X, Boston University, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lienhardt","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Montpellier, INSERM, Institut de Recherche pour le D\u00e9veloppement, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin","family":"Spigelman","sequence":"additional","affiliation":[{"name":"TB Alliance, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn L.","family":"Silver","sequence":"additional","affiliation":[{"name":"LL Silver Consulting, Springfield, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Ohmagari","sequence":"additional","affiliation":[{"name":"National Center for Global Health and Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Kozlov","sequence":"additional","affiliation":[{"name":"Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, Smolensk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Harbarth","sequence":"additional","affiliation":[{"name":"National Center for Infection Prevention, Swissnoso, Bern, Switzerland"},{"name":"Infection Control Programme, Geneva University Hospitals and Faculty of Medicine, WHO Collaborating Center for Patient Safety, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Beyer","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Division, WHO, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2020.06.009"},{"key":"e_1_3_3_3_2","unstructured":"Global AMR R&D Hub. 2021. Estimating global patient needs and market potential for priority health technologies addressing antimicrobial resistance. https:\/\/globalamrhub.org\/our-work\/studies\/market-potential-and-priority-patient-needs\/. Global AMR R&D Hub Berlin Germany."},{"key":"e_1_3_3_4_2","unstructured":"World Health Organization. 2017. WHO publishes list of bacteria for which new antibiotics are urgently needed. https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. WHO Geneva Switzerland."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32063-8"},{"key":"e_1_3_3_7_2","unstructured":"The Pew Charitable Trusts. 2021. Tracking the global pipeline of antibiotics in development March 2021. https:\/\/www.pewtrusts.org\/en\/research-and-analysis\/issue-briefs\/2021\/03\/tracking-the-global-pipeline-of-antibiotics-in-development. The Pew Charitable Trusts Philadelphia PA."},{"key":"e_1_3_3_8_2","volume-title":"Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis.","author":"World Health Organization.","year":"2017","unstructured":"World Health Organization. 2017. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_9_2","volume-title":"Update of antibacterial agents in clinical development 2018","author":"World Health Organization.","year":"2018","unstructured":"World Health Organization. 2018. Update of antibacterial agents in clinical development 2018, Geneva, Switzerland."},{"key":"e_1_3_3_10_2","volume-title":"2019 antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline.","author":"World Health Organization.","year":"2019","unstructured":"World Health Organization. 2019. 2019 antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_11_2","volume-title":"2020 antibacterial agents in clinical and preclinical development: an overview and analysis.","author":"World Health Organization.","year":"2021","unstructured":"World Health Organization. 2021. 2020 antibacterial agents in clinical and preclinical development: an overview and analysis. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_12_2","unstructured":"Centres for Disease Control and Prevention. 2019. Biggest threats and data 2019 antibiotic resistance threats report. https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html. CDC Washington DC."},{"key":"e_1_3_3_13_2","unstructured":"The Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States 2013. https:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/pdf\/ar-threats-2013-508.pdf. CDC Washington DC."},{"key":"e_1_3_3_14_2","unstructured":"WHO Country Office for India and Department of Biotechnology Government of India. 2021. Indian priority pathogen list. To guide research discovery and development of new antibiotics in India. https:\/\/dbtindia.gov.in\/sites\/default\/files\/IPPL_final.pdf. World Health Organization Geneva Switzerland."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa852"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41429-021-00414-5"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa859"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa464"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/M20-7355"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2014.07.005"},{"key":"e_1_3_3_21_2","unstructured":"World Health Organization. 2020. A financial model for an impact investment fund for the development of antibacterial treatments and diagnostics. https:\/\/www.who.int\/publications\/i\/item\/a-financial-model-for-an-impact-investment-fund-for-the-development-of-antibacterial-treatments-and-diagnostics-a-user-guide. World Health Organization Geneva Switzerland."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2020.11.015"},{"key":"e_1_3_3_23_2","unstructured":"AMR Alliance Japan. 2021. Creating pull incentives for antimicrobials (March 24 2021). https:\/\/hgpi.org\/en\/research\/amr-21.html. Health and Global Policy Institute Tokyo Japan."},{"key":"e_1_3_3_24_2","unstructured":"International Federation of Pharmaceutical Manufacturers and Associations. 2021. Global principles on incentivizing antibiotic R&D. https:\/\/www.ifpma.org\/resource-centre\/global-principles-on-incentivizing-antibiotic-rd\/. IFPMA Geneva Switzerland."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00681"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2021.00688"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix526"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2468"},{"key":"e_1_3_3_29_2","unstructured":"Rex JH Outterson K. 2020. UK antibiotic subscription pilot implies pull incentive of up to $4b across the G20. https:\/\/amr.solutions\/2020\/03\/29\/uk-antibiotic-subscription-pilot-implies-pull-incentive-of-up-to-4b-across-the-g20\/."},{"key":"e_1_3_3_30_2","unstructured":"Rex JH Krause KM. 2021. 21st century cures V2.0 \u2014 PASTEUR act is embedded! https:\/\/amr.solutions\/2021\/06\/22\/21st-century-cures-v2-0-pasteur-act-is-embedded\/."},{"key":"e_1_3_3_31_2","unstructured":"Vorperian S Quake S. 2021. The PASTEUR Act can help win the war against superbugs on STAT News. https:\/\/www.statnews.com\/2021\/06\/25\/pasteur-act-help-fight-superbugs-antimicrobial-resistance\/. STAT Boston MA."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00466-1"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2019.06.004"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11303-9"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0577-0"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00314-5"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2015.01320"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182879"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.3390\/app10072605"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2018.04.001"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236604"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41429-020-0291-8"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30513-9"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-0340-0"},{"key":"e_1_3_3_45_2","volume-title":"Antimicrobial resistance benchmark 2020.","author":"Access to Medicine Foundation.","year":"2020","unstructured":"Access to Medicine Foundation. 2020. Antimicrobial resistance benchmark 2020. Amsterdam, The Netherlands."},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01576-0"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2476"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz826"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01443-4"},{"key":"e_1_3_3_50_2","volume-title":"Iterum therapeutics receives complete response letter from U.S. Food and Drug Administration for oral sulopenem.","author":"Iterum Therapeutics.","year":"2021","unstructured":"Iterum Therapeutics. 2021. Iterum therapeutics receives complete response letter from U.S. Food and Drug Administration for oral sulopenem. https:\/\/www.iterumtx.com\/news\/press-releases\/detail\/73\/iterum-therapeutics-receives-complete-response-letter-from. Iterum Therapeutics, Dublin, Ireland."},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01659-20"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1159"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02240-19"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1496821"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01517-20"},{"key":"e_1_3_3_56_2","unstructured":"MicuRx. 2021. Pipeline MRX-8. http:\/\/www.micurx.com\/pipeline. MicuRx Shanghai China."},{"key":"e_1_3_3_57_2","unstructured":"Monash University. 2021. New antibiotic to combat deadly bacterial \u2018superbugs\u2019 enters clinical trials. https:\/\/www.monash.edu\/discovery-institute\/news-and-events\/news\/2021-articles\/new-antibiotic-to-combat-deadly-bacterial-superbugs-enters-clinical-trials. Monash University Clayton Australia."},{"key":"e_1_3_3_58_2","unstructured":"Qpex Biopharma. 2021. Qpex Biopharma initiates phase 1 study of QPX9003 targeting antibiotic-resistant pathogens. https:\/\/www.qpexbio.com\/qpexbiopharmaqpx9003. Qpex Biopharma San Diego CA."},{"key":"e_1_3_3_59_2","unstructured":"Sinovent. 2021. FDA approved QIDP and FTD of XNW4107. https:\/\/www.sinovent.com.cn\/en\/News\/info.aspx?itemid=124. Sinovent Jiangsu People\u2019s Republic of China."},{"key":"e_1_3_3_60_2","unstructured":"TenNor Therapeutics. 2020. TenNor initiated TNP-2198 phase 1b\/IIa clinical trials. http:\/\/www.tennorx.com\/en\/h-nd-63.html. TenNor Therapeutics Jiangsu China."},{"key":"e_1_3_3_61_2","unstructured":"Working Group on New TB Drugs. 2021. Clinical pipeline. https:\/\/www.newtbdrugs.org\/pipeline\/clinical. The Working Group for New TB Drugs New York NY."},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2019.115213"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02418-20"},{"key":"e_1_3_3_64_2","unstructured":"Pages LB Aguirre DB Bates RH Pichel JC Provencio JE Pethe K. 2017. Antituberculosis agent. US Patent US10."},{"key":"e_1_3_3_65_2","unstructured":"Working Group on New TB Drugs. 2021. GSK-286. https:\/\/www.newtbdrugs.org\/pipeline\/compound\/gsk-286. The Working Group for New TB Drugs New York NY."},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-018-5229-2"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI136577"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000004102"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa387"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.16.10"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00843-9"},{"key":"e_1_3_3_72_2","unstructured":"Seres Therapeutics. 2020. Seres therapeutics announces positive topline results from SER-109 phase 3 ECOSPOR III study in recurrent C difficile infection. https:\/\/ir.serestherapeutics.com\/news-releases\/news-release-details\/seres-therapeutics-announces-positive-topline-results-ser-109. Seres Therapeutics Cambridge MA."},{"key":"e_1_3_3_73_2","unstructured":"BiomeBank. 2021. BiomeBank submits for market authorisation of world first microbial therapy. https:\/\/www.biomebank.com\/news\/biome-bank-submits-for-market-authorisation-of-world-first-microbial-therapy. BiomeBank Thebarton Australia."},{"key":"e_1_3_3_74_2","unstructured":"Atox Bio. 2020. Atox Bio announces FDA acceptance to file the NDA for reltecimod to treat suspected organ dysfunction or failure in patients with necrotizing soft tissue infection (\u201cflesh-eating disease\u201d). https:\/\/www.atoxbio.com\/news\/. Atox Bio Durham NC."},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98960"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00904-17"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219256"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aag1006"},{"key":"e_1_3_3_79_2","unstructured":"Working Group on New TB Drugs. 2021. BVL-GSK098. https:\/\/www.newtbdrugs.org\/pipeline\/compound\/bvl-gsk098. Working Group on New TB Drugs New York NY."},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2021.115471"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00508-21"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.06.009"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.005732"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3262"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.113139"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41429-020-00396-w"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9070397"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4609"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2201"},{"key":"e_1_3_3_90_2","unstructured":"CARB-X. 2021. CARB-X celebrates five years of progress in early-stage product development against antibiotic-resistant bacteria. https:\/\/carb-x.org\/carb-x-news\/carb-x-celebrates-five-years-of-progress-in-early-stage-product-development-against-antibiotic-resistant-bacteria\/. CARB-X Boston MA."},{"key":"e_1_3_3_91_2","unstructured":"GARDP. 2021. Research & development. https:\/\/gardp.org\/what-we-do\/research-development\/. GARDP Geneva Switzerland."},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00143-8"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41429-019-0205-9"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003059"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.1c00331"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00026"},{"key":"e_1_3_3_97_2","unstructured":"ND4BB ENABLE. 2021. European Gram Negative AntiBacterial Engine ENABLE. http:\/\/nd4bb-enable.eu\/enable-portfolio. ND4BB ENABLE Brussels Belgium."},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.03058-20"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00159-19"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00432-19"},{"key":"e_1_3_3_101_2","unstructured":"Peptilogics. 2021. First-in-human data show PLG0206 intravenously administered was well tolerated in healthy volunteers with linear PK over the dose range. https:\/\/www.peptilogics.com\/news\/peptilogics-presents-positive-first-in-human-phase-1-data-for-its-lead-engineered-antibacterial-peptide-plg0206-at-idweek-2021\/. Peptilogics Pittsburgh PA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01991-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01991-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T15:05:27Z","timestamp":1647356727000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01991-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,15]]}},"alternative-id":["10.1128\/aac.01991-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.01991-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]},"assertion":[{"value":"2022-03-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01991-21"}}